文献速递神经肿瘤

H3K27M弥漫性中线胶质瘤存在同源重组缺陷,PARP抑制可使其对放疗和NK细胞介导的抗肿瘤免疫增敏

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition.
PubMed 文献 · Neuro Oncol · 2025-01-01

本研究在H3K27M同基因DMG细胞和原位脑干DMG小鼠模型中,评估奥拉帕利或AZD9574联合放疗的疗效与机制。H3K27M突变导致同源重组修复缺陷,PARP抑制选择性增加H3K27M DMG细胞放疗敏感性,并诱导NK细胞介导的抗肿瘤免疫反应,支持PARP1抑制剂联合放疗的临床研究。

要点

  • H3K27M突变导致同源重组修复缺陷,表现为放疗诱导的组蛋白H1 K63连接多泛素化受损和HRR蛋白募集受抑。
  • 奥拉帕利选择性增敏H3K27M DMG细胞的放疗效果,并在H3K27M原位脑干肿瘤中转化疗效。
  • 奥拉帕利联合放疗诱导先天免疫反应和NKG2D激活配体,增强NK细胞对DMG细胞的裂解。

核心结论

  • H3K27M DMG的同源重组修复缺陷可利用PARP抑制剂进行选择性放疗增敏并诱导NK细胞介导的抗肿瘤免疫反应,支持PARP1抑制剂联合放疗在DMG患者中的临床研究。

研究设计与样本

  • 研究使用H3K27M同基因DMG细胞以及免疫缺陷和同基因免疫健全小鼠的原位脑干DMG肿瘤,评估奥拉帕利或AZD9574联合放疗的疗效与机制。

主要发现

  • H3K27M突变导致同源重组修复缺陷,特征为放疗诱导的组蛋白H1 K63连接多泛素化受损和HRR蛋白募集受抑。
  • 与同基因对照相比,奥拉帕利选择性增敏H3K27M DMG细胞的放疗效果,并在H3K27M原位脑干肿瘤中转化疗效。
  • 奥拉帕利联合放疗诱导先天免疫反应和NKG2D激活配体,增加NK细胞对DMG细胞的裂解。
  • 在免疫健全同基因原位DMG肿瘤中,奥拉帕利或AZD9574联合放疗增强瘤内NK细胞浸润和活性,与NK细胞介导的治疗反应及AZD9574的良好活性相关。

临床怎么用

  • 原文结论支持在DMG患者中开展PARP1抑制剂联合放疗的临床研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy (RT) is the primary treatment for diffuse midline glioma (DMG), a lethal pediatric malignancy defined by histone H3 lysine 27-to-methionine (H3K27M) mutation. Based on the loss of H3K27 trimethylation producing broad epigenomic alterations, we hypothesized that H3K27M causes a functional double-strand break (DSB) repair defect that could be leveraged therapeutically with PARP inhibitor and RT for selective radiosensitization and antitumor immune response. METHODS: H3K27M isogenic DMG cells and orthotopic brainstem DMG tumors in immune deficient and syngeneic, immune competent mice were used to evaluate the efficacy and mechanisms of PARP1/2 inhibition by olaparib or PARP1-selective inhibition by AZD9574 with concurrent RT. RESULTS: H3K27M mutation caused a homologous recombination repair (HRR) defect characterized by impaired RT-induced K63-linked polyubiquitination of histone H1 and inhibition of HRR protein recruitment. H3K27M DMG cells were selectively radiosensitized by olaparib in comparison to isogenic controls, and this effect translated to efficacy in H3K27M orthotopic brainstem tumors. Olaparib and RT induced an innate immune response and induction of NK cell (NKG2D) activating ligands leading to increased NK cell-mediated lysis of DMG cells. In immunocompetent syngeneic orthotopic DMG tumors, either olaparib or AZD9574 in combination with RT enhanced intratumoral NK cell infiltration and activity in association with NK cell-mediated therapeutic responses and favorable activity of AZD9574. CONCLUSIONS: The HRR deficiency in H3K27M DMG can be therapeutically leveraged with PARP inhibitors to radiosensitize and induce an NK cell-mediated antitumor immune response selectively in H3K27M DMG, supporting the clinical investigation of PARP1 inhibitors with RT in DMG patients.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Guo Y, Li Z, Parsels LA, et al. H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibition. Neuro Oncol. 2025. PMID: 40207661. doi:10.1093/neuonc/noaf097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。